Main Street Financial Solutions LLC Sells 67 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Main Street Financial Solutions LLC trimmed its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,543 shares of the medical equipment provider’s stock after selling 67 shares during the quarter. Main Street Financial Solutions LLC’s holdings in Intuitive Surgical were worth $758,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. International Assets Investment Management LLC increased its stake in Intuitive Surgical by 49,383.6% in the third quarter. International Assets Investment Management LLC now owns 1,090,619 shares of the medical equipment provider’s stock valued at $535,788,000 after acquiring an additional 1,088,415 shares during the period. Capital Research Global Investors acquired a new stake in Intuitive Surgical in the 1st quarter valued at $374,390,000. Vanguard Group Inc. boosted its stake in Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares in the last quarter. Strategic Financial Concepts LLC grew its position in Intuitive Surgical by 40,221.4% in the second quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock valued at $1,184,000 after acquiring an additional 265,461 shares during the period. Finally, GQG Partners LLC bought a new position in shares of Intuitive Surgical during the first quarter valued at $99,523,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Ratings Changes

ISRG has been the subject of several analyst reports. Piper Sandler reissued an “overweight” rating and set a $538.00 price target (up from $495.00) on shares of Intuitive Surgical in a report on Friday, October 18th. Barclays boosted their target price on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Citigroup raised their target price on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Truist Financial boosted their price objective on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average price target of $513.74.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, General Counsel Gary Loeb sold 300 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $475.00, for a total value of $142,500.00. Following the completion of the transaction, the general counsel now owns 1,595 shares of the company’s stock, valued at approximately $757,625. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 91,178 shares of company stock valued at $45,897,071. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $536.69 on Thursday. Intuitive Surgical, Inc. has a 1 year low of $287.98 and a 1 year high of $542.59. The company has a market capitalization of $191.16 billion, a P/E ratio of 86.28, a price-to-earnings-growth ratio of 5.28 and a beta of 1.39. The business has a 50-day moving average of $495.85 and a two-hundred day moving average of $455.08.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, topping the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.